Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine
Top Cited Papers
- 20 June 2007
- journal article
- melanoma
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18) , 2546-2553
- https://doi.org/10.1200/jco.2006.08.5829
Abstract
Purpose: Phenotypic and functional features of myeloid suppressor cells (MSC), which are known to serve as critical regulators of antitumor T-cell responses in tumor-bearing mice, are still poorly defined in human cancers. Here, we analyzed myeloid subsets with suppressive activity present in peripheral blood of metastatic melanoma patients and evaluated their modulation by a granulocyte-macrophage colony-stimulating factor (GM-CSF) –based antitumor vaccine.Patients and Methods: Stage IV metastatic melanoma patients (n = 16) vaccinated with autologous tumor-derived heat shock protein peptide complex gp96 (HSPPC-96) and low-dose GM-CSF provided pre- and post-treatment whole blood specimens. Peripheral-blood mononuclear cells (PBMCs) were analyzed by flow cytometry, separated into cellular subsets, and used for in vitro proliferation assays. PBMCs from stage-matched metastatic melanoma patients (n = 12) treated with non–GM-CSF-based vaccines (ie, HSPPC-96 alone or interferon alfa/melanoma–derived peptides) or sex- and age-matched healthy donors (n = 16) were also analyzed for comparison.Results: The lack of or low HLA-DR expression was found to identify a CD14+cell subset highly suppressive of lymphocyte functions. CD14+HLA-DR–/locells were significantly expanded in all metastatic melanoma patients, whereas they were undetectable in healthy donors. Suppressive activity was mediated by transforming growth factor beta (TGF-β), whereas no involvement of the arginase and inducible nitric oxide synthase pathways could be detected. CD14+HLA-DR–/locells, as well as spontaneous ex vivo release and plasma levels of TGF-β, were augmented after administration of the HSPPC-96/GM-CSF vaccine. No enhancement of the CD14+-mediated suppressive activity was found in patients receiving non–GM-CSF-based vaccines.Conclusion: CD14+HLA-DR–/locells exerting TGF-β–mediated immune suppression represent a new subset of MSC potentially expandable by the administration of GM-CSF–based vaccines in metastatic melanoma patients.Keywords
This publication has 34 references indexed in Scilit:
- Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patientsAnnals of Oncology, 2006
- Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-β–Mediated Suppressive Activity on T LymphocytesCancer Research, 2006
- Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell PrecursorsCancer Research, 2006
- HUMAN T CELL RESPONSES AGAINST MELANOMAAnnual Review of Immunology, 2006
- TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillanceCancer Cell, 2005
- Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferationThe Journal of Experimental Medicine, 2005
- Regulation of immune responses by L-arginine metabolismNature Reviews Immunology, 2005
- High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor CellsCancer Research, 2004
- On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma PatientsClinical Cancer Research, 2004
- Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+ progenitor cellsHuman Immunology, 2001